Invida Pharmaceutical Holdings to Present at the 28th Annual JP Morgan Healthcare Conference

SINGAPORE--(Marketwire - January 04, 2010) - Invida Pharmaceutical Group, the leading commercialization and licensing partner of healthcare products in Asia, today announced that the company has been selected to present at the 2010 JP Morgan Healthcare Conference on Tuesday, January 12, 2010 at 7:30 AM PST. The presentation will be webcast live and available on the company’s website at http://www.invida.com/media.html. CEO John A. Graham will provide an updated overview of the Company, its strategy for 2010 and key partnering opportunities for growth in Asia Pacific.

John A. Graham, Chief Executive Officer, said, “We are delighted to be invited, and to kick off our 2010 corporate initiatives at JP Morgan. Further, this provides us the opportunity to introduce Invida to top healthcare investors and pharmaceutical companies, and to highlight opportunities for our continued growth as the premier marketing partner in the Asia Pacific markets. In 2010, Invida will continue to build on its 20 years of pharmaceutical commercialization experience in Asia and accelerate growth in key Asia Pacific markets, both for our partners’ brands and our own. The JP Morgan conference is a great venue to update our stakeholders on our progress and continued success.”

Invida is a pharmaceutical company primarily engaged in the licensing, marketing and distribution of prescription and over-the-counter therapeutic products throughout the Asia Pacific region. Its current roster of partners includes top multinational pharmaceutical companies and leaders in cutting-edge consumer healthcare products. By facilitating the commercialization of these products throughout Asia, Invida provides a unique opportunity for partners and investors to expand their reach to these audiences and provide quality pharmaceutical products to the rapidly expanding and dynamic Asian markets.

About Invida

Invida improves the lives of patients in Asia by commercializing differentiated pharmaceutical products of superior quality -- the result of which will allow all our stakeholders to prosper. We do this through our proven brand marketing and sales know-how, strong expertise across a number of key therapeutic categories and deep experience in all critical Asian markets. Comprehensive functional capabilities provide rapid market access delivered by our passionate team of professionals.

With more than 4, 000 employees in 13 countries in Asia Pacific, Invida operates across the commercial value chain from regulatory approval and product launch to lifecycle management. We manage a portfolio of proprietary healthcare brands as well as licensed products from small biotech firms and large multinational companies. Partnering is a critical component of Invida’s business model. We collaborate closely with our partners in developing effective strategies and put our extensive experience behind maximizing the potential of the assets entrusted to us.